Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Extracellular Vesicles as Therapeutic Resources in the Clinical Environment

Sanz-Ros J., Mas-Bargues C., Romero-García N., Huete-Acevedo J., Dromant M., Borrás C.

Clinical Trial, published in Int J Mol Sci (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2023)
Reported sample size
—
Source database
Europe PMC
PMID
36768664
PMCID
PMC9917082
DOI
10.3390/ijms24032344
Citations
56

Abstract (original English)

The native role of extracellular vesicles (EVs) in mediating the transfer of biomolecules between cells has raised the possibility to use them as therapeutic vehicles. The development of therapies based on EVs is now expanding rapidly; here we will describe the current knowledge on different key points regarding the use of EVs in a clinical setting. These points are related to cell sources of EVs, isolation, storage, and delivery methods, as well as modifications to the releasing cells for improved production of EVs. Finally, we will depict the application of EVs therapies in clinical trials, considering the impact of the COVID-19 pandemic on the development of these therapies, pointing out that although it is a promising therapy for human diseases, we are still in the initial phase of its application to patients.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansExcipientsDrug Delivery SystemsPandemicsExtracellular VesiclesCOVID-19

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.